Pseudomembranous enterocolitis: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
Line 33: Line 33:


====Antibiotics====
====Antibiotics====
Observational cohort [[study|studies]] conflict regarding the best agent and suggest [[vancomycin]] may<ref name="pmid12135033">{{cite journal |author=McFarland LV, Elmer GW, Surawicz CM |title=Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease |journal=Am. J. Gastroenterol. |volume=97 |issue=7 |pages=1769–75 |year=2002 |month=July |pmid=12135033 |doi=10.1016/S0002-9270(02)04195-3 |url= |issn=}}</ref> or may not<ref name="pmid16477549">{{cite journal |author=Pépin J, Routhier S, Gagnon S, Brazeau I |title=Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada |journal=Clin. Infect. Dis. |volume=42 |issue=6 |pages=758–64 |year=2006 |month=March |pmid=16477549 |doi=10.1086/501126 |url=http://www.journals.uchicago.edu/doi/abs/10.1086/501126?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov |issn=}}</ref> be better than [[metronidazole]]. Various methods exist for the administration of [[vancomycin]]<ref name="pmid12135033">{{cite journal |author=McFarland LV, Elmer GW, Surawicz CM |title=Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease |journal=Am. J. Gastroenterol. |volume=97 |issue=7 |pages=1769–75 |year=2002 |month=July |pmid=12135033 |doi=10.1016/S0002-9270(02)04195-3 |url= |issn=}}</ref><ref name="pmid4050760">{{cite journal |author=Tedesco FJ, Gordon D, Fortson WC |title=Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis |journal=Am. J. Gastroenterol. |volume=80 |issue=11 |pages=867–8 |year=1985 |month=November |pmid=4050760 |doi= |url= |issn=}}</ref>
Observational [[cohort study|studies]] conflict regarding the best agent and suggest [[vancomycin]] may<ref name="pmid12135033">{{cite journal |author=McFarland LV, Elmer GW, Surawicz CM |title=Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease |journal=Am. J. Gastroenterol. |volume=97 |issue=7 |pages=1769–75 |year=2002 |month=July |pmid=12135033 |doi=10.1016/S0002-9270(02)04195-3 |url= |issn=}}</ref> or may not<ref name="pmid16477549">{{cite journal |author=Pépin J, Routhier S, Gagnon S, Brazeau I |title=Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada |journal=Clin. Infect. Dis. |volume=42 |issue=6 |pages=758–64 |year=2006 |month=March |pmid=16477549 |doi=10.1086/501126 |url=http://www.journals.uchicago.edu/doi/abs/10.1086/501126?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov |issn=}}</ref> be better than [[metronidazole]]. Various methods exist for the administration of [[vancomycin]]<ref name="pmid12135033">{{cite journal |author=McFarland LV, Elmer GW, Surawicz CM |title=Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease |journal=Am. J. Gastroenterol. |volume=97 |issue=7 |pages=1769–75 |year=2002 |month=July |pmid=12135033 |doi=10.1016/S0002-9270(02)04195-3 |url= |issn=}}</ref><ref name="pmid4050760">{{cite journal |author=Tedesco FJ, Gordon D, Fortson WC |title=Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis |journal=Am. J. Gastroenterol. |volume=80 |issue=11 |pages=867–8 |year=1985 |month=November |pmid=4050760 |doi= |url= |issn=}}</ref>
 
{| class="wikitable"
|+ [[Cohort study|Cohort studies]] of the treatment of Clostridium difficile associated diarrhea
! &nbsp;!! Patients !! Intervention / duration!! Comparison !! Outcome<br/>Recurrence rate
|-
| Vancomycin constant dose<ref name="pmid12135033"/>||83 patients||0.5 to 3 grams/day<br/>10 - 16 days||align="center"|NA||54%
|-
| &nbsp;&nbsp;&nbsp;high dose<ref name="pmid12135033"/>||21 patients|| ≥2 grams/day<br/>10 - 16 days||align="center"|NA||&nbsp;&nbsp;&nbsp;43%
|-
| &nbsp;&nbsp;&nbsp;medium dose<ref name="pmid12135033"/>||14 patients|| 1 - 2 grams/day<br/>10 - 16 days||align="center"|NA||&nbsp;&nbsp;&nbsp;71%
|-
| &nbsp;&nbsp;&nbsp;low dose<ref name="pmid12135033"/>||48 patients|| < 1 grams/day<br/>10 - 16 days||align="center"|NA||&nbsp;&nbsp;&nbsp;54%
|-
| Metronidazole constant dose<ref name="pmid12135033"/>||36 patients||0.5 to 3 grams/day<br/>10 - 16 days||align="center"|NA||42%
|-
|Vancomycin pulsed regimen<ref name="pmid16477549"/>||7 patients||0.5 to 2 grams daily<br/>10 - 14 days||align="center"|NA||40%
|-
|Metronidazole pulsed regimen<ref name="pmid16477549"/>||7 patients||1.0 to 1.5 grams per day<br/>10 - 14 days||align="center"|NA||37%
|-
|Vancomycin tapered regimen<ref name="pmid12135033"/>||29 patients||Varying doses<br/>21.5 ± 10.0 days||align="center"|NA||31%
|-
|Vancomycin pulsed regimen<ref name="pmid12135033"/>||7 patients||Varying doses<br/>21 days||align="center"|NA||14%
|-
|Vancomycin followed by rifaximin<ref name="pmid17304459"/>||8 patients||Vancomycin followed by rifaximin 400–800 mg daily for 14 days<br/>≥ 21 days||align="center"|NA||13%
|-
|Vancomycin tapered regimen<ref name="pmid4050760"/>||22 patients||125 mg four times daily tapered to 125 mg every third day<br/>42 days||align="center"|NA||0%
|}


Serial therapy with [[vancomycin]] and [[rifaximin]] has been studied in a small uncontrolled series of patients.<ref name="pmid17304459">{{cite journal |author=Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN |title=Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin |journal=Clin. Infect. Dis. |volume=44 |issue=6 |pages=846–8 |year=2007 |month=March |pmid=17304459 |doi=10.1086/511870 |url=http://www.journals.uchicago.edu/doi/abs/10.1086/511870?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov |issn=}}</ref>
Serial therapy with [[vancomycin]] and [[rifaximin]] has been studied in a small uncontrolled series of patients.<ref name="pmid17304459">{{cite journal |author=Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN |title=Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin |journal=Clin. Infect. Dis. |volume=44 |issue=6 |pages=846–8 |year=2007 |month=March |pmid=17304459 |doi=10.1086/511870 |url=http://www.journals.uchicago.edu/doi/abs/10.1086/511870?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov |issn=}}</ref>
<references/>


====Administration of bacteria====
====Administration of bacteria====

Revision as of 00:07, 12 February 2009

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Pseudomembranous_enterocolitis&printable=yes
This editable Main Article is under development and subject to a disclaimer.
Pseudomembranous enterocolitis
Img1.jpg

Pseudomembranous enterocolitis
MeSH D004761

In medicine, pseudomembranous enterocolitis is an "acute inflammation of the intestinal mucosa that is characterized by the presence of pseudomembranes or plaques in the small intestine (pseudomembranous enteritis) and the large intestine (pseudomembranous colitis). It is commonly associated with antibiotic therapy and clostridium difficile colonization."[1]

Epidemiology

About 50% of patients with diarrhea after antibiotics that is severe enough to be admitted to the hospital have pseudomembranes on colonoscopy.[2]

Diagnosis

Sigmoidoscopy has a sensitivity of 31% in detecting pseudomembranes as compared to colonosopy.[3]

Treatment

Antibiotics

Various antibiotics have been studied in randomized controlled trials.[4][5][6] Teicoplanin may be the most effective antibiotic.[4][5] Vancomycin has an insignificant trend towards being better than metronidazole.[4]

Administration of bacteria

Probiotic administration may[7] or may not [8]help according to a meta-analyses and a more recent randomized controlled trial.[9] However, probiotics can be harmful among intensive care patients.[10]

Recurrent infection

A clinical prediction rule found that recurrent infection is more likely if age is more than 65 years, the patient has severe or fulminant illness, and additional antibiotic exposure occurs after after treatment of the initial Clostridium difficile infection.[11] Use of antacids may also be a risk factor for recurrence.[12]

Asymptomatic carriage should not be treated according to a meta-analysis.[13]

Antibiotics

Observational studies conflict regarding the best agent and suggest vancomycin may[14] or may not[15] be better than metronidazole. Various methods exist for the administration of vancomycin[14][16]

Cohort studies of the treatment of Clostridium difficile associated diarrhea
  Patients Intervention / duration Comparison Outcome
Recurrence rate
Vancomycin constant dose[14] 83 patients 0.5 to 3 grams/day
10 - 16 days		 NA 54%
   high dose[14] 21 patients ≥2 grams/day
10 - 16 days		 NA    43%
   medium dose[14] 14 patients 1 - 2 grams/day
10 - 16 days		 NA    71%
   low dose[14] 48 patients < 1 grams/day
10 - 16 days		 NA    54%
Metronidazole constant dose[14] 36 patients 0.5 to 3 grams/day
10 - 16 days		 NA 42%
Vancomycin pulsed regimen[15] 7 patients 0.5 to 2 grams daily
10 - 14 days		 NA 40%
Metronidazole pulsed regimen[15] 7 patients 1.0 to 1.5 grams per day
10 - 14 days		 NA 37%
Vancomycin tapered regimen[14] 29 patients Varying doses
21.5 ± 10.0 days		 NA 31%
Vancomycin pulsed regimen[14] 7 patients Varying doses
21 days		 NA 14%
Vancomycin followed by rifaximin[17] 8 patients Vancomycin followed by rifaximin 400–800 mg daily for 14 days
≥ 21 days		 NA 13%
Vancomycin tapered regimen[16] 22 patients 125 mg four times daily tapered to 125 mg every third day
42 days		 NA 0%

Serial therapy with vancomycin and rifaximin has been studied in a small uncontrolled series of patients.[17]

  1. ↑ Anonymous (2024), Pseudomembranous enterocolitis (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ Lee KS, Shin WG, Jang MK, et al (October 2006). "Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea?". Dis. Colon Rectum 49 (10): 1552–8. DOI:10.1007/s10350-006-0694-z. PMID 17028914. Research Blogging.
  3. ↑ Seppala, K, Hjelt, L, Supponen, P. Colonoscopy in the diagnosis of antibiotic-associated colitis. Scand J Gastroenterol 1981; 16:465. PMID 7323683
  4. ↑ 4.0 4.1 4.2 Nelson R (2007). "Antibiotic treatment for Clostridium difficile-associated diarrhea in adults". Cochrane Database Syst Rev (3): CD004610. DOI:10.1002/14651858.CD004610.pub3. PMID 17636768. Research Blogging.
  5. ↑ 5.0 5.1 Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W (May 1996). "Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea". Clin. Infect. Dis. 22 (5): 813–8. PMID 8722937. [e]
  6. ↑ Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF (January 2009). "Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study". Clin. Infect. Dis.. DOI:10.1086/596552. PMID 19133801. Research Blogging.
  7. ↑ McFarland LV (April 2006). "Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease". Am. J. Gastroenterol. 101 (4): 812–22. DOI:10.1111/j.1572-0241.2006.00465.x. PMID 16635227. Research Blogging.
  8. ↑ Pillai A, Nelson R (2008). "Probiotics for treatment of Clostridium difficile-associated colitis in adults". Cochrane Database Syst Rev (1): CD004611. DOI:10.1002/14651858.CD004611.pub2. PMID 18254055. Research Blogging.
  9. ↑ Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B (September 2008). "Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics". Acta Anaesthesiol Scand 52 (8): 1096–102. DOI:10.1111/j.1399-6576.2008.01748.x. PMID 18840110. Research Blogging.
  10. ↑ Muñoz P, Bouza E, Cuenca-Estrella M, et al (June 2005). "Saccharomyces cerevisiae fungemia: an emerging infectious disease". Clin. Infect. Dis. 40 (11): 1625–34. DOI:10.1086/429916. PMID 15889360. Research Blogging.
  11. ↑ Hu MY, Katchar K, Kyne L, et al (December 2008). "Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection". Gastroenterology. DOI:10.1053/j.gastro.2008.12.038. PMID 19162027. Research Blogging.
  12. ↑ Garey KW, Sethi S, Yadav Y, DuPont HL (December 2008). "Meta-analysis to assess risk factors for recurrent Clostridium difficile infection". J. Hosp. Infect. 70 (4): 298–304. DOI:10.1016/j.jhin.2008.08.012. PMID 18951661. Research Blogging.
  13. ↑ Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN (February 1998). "Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea". Lancet 351 (9103): 633–6. DOI:10.1016/S0140-6736(97)08062-8. PMID 9500319. Research Blogging.
  14. ↑ 14.0 14.1 14.2 14.3 14.4 14.5 14.6 14.7 14.8 McFarland LV, Elmer GW, Surawicz CM (July 2002). "Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease". Am. J. Gastroenterol. 97 (7): 1769–75. DOI:10.1016/S0002-9270(02)04195-3. PMID 12135033. Research Blogging.
  15. ↑ 15.0 15.1 15.2 Pépin J, Routhier S, Gagnon S, Brazeau I (March 2006). "Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada". Clin. Infect. Dis. 42 (6): 758–64. DOI:10.1086/501126. PMID 16477549. Research Blogging.
  16. ↑ 16.0 16.1 Tedesco FJ, Gordon D, Fortson WC (November 1985). "Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis". Am. J. Gastroenterol. 80 (11): 867–8. PMID 4050760. [e]
  17. ↑ 17.0 17.1 Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN (March 2007). "Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin". Clin. Infect. Dis. 44 (6): 846–8. DOI:10.1086/511870. PMID 17304459. Research Blogging.

Administration of bacteria

Probiotics may help.[1] However, probiotics can be harmful among intensive care patients.[2]

Rectal infusion of feces helped according to case reports.[3][4]

References

  1. ↑ Surawicz CM (July 2008). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". J. Clin. Gastroenterol. 42 Suppl 2: S64–70. DOI:10.1097/MCG.0b013e3181646d09. PMID 18545161. Research Blogging.
  2. ↑ Muñoz P, Bouza E, Cuenca-Estrella M, et al (June 2005). "Saccharomyces cerevisiae fungemia: an emerging infectious disease". Clin. Infect. Dis. 40 (11): 1625–34. DOI:10.1086/429916. PMID 15889360. Research Blogging.
  3. ↑ Schwan A, Sjölin S, Trottestam U, Aronsson B (October 1983). "Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces". Lancet 2 (8354): 845. PMID 6137662. [e]
  4. ↑ Nieuwdorp M, van Nood E, Speelman P, et al (August 2008). "[Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces]" (in Dutch; Flemish). Ned Tijdschr Geneeskd 152 (35): 1927–32. PMID 18808083. [e]
Retrieved from "https://citizendium.org/wiki/index.php?title=Pseudomembranous_enterocolitis&oldid=576197"